Stockscreener 앱 받기
27.46
3.70%
0.98
시간 외 거래:
27.46
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
What hedge funds are buying Rapport Therapeutics Inc2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
BTIG raises Rapport Therapeutics stock price target on trial progress By Investing.com - Investing.com Canada
Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress - Investing.com Canada
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
Rapport’s RAP-219 gets more phase III funding with Tenacia deal - BioWorld MedTech
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings - MarketBeat
Rapport Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Rapport Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Rapport Therapeutics 2025 10‑K: Net loss $111.5M, EPS $(2.86) - TradingView
Rapport Therapeutics (Nasdaq: RAPP) details 2025 losses and RAP‑219 epilepsy progress - Stock Titan
RAP-219 epilepsy drug cut seizures 77.8% in Phase 2a trial - Stock Titan
Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Top Executive’s Surprise Stock Move Shakes Up Rapport Therapeutics - TipRanks
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
BTIG reiterates Rapport Therapeutics stock rating citing selectivity By Investing.com - Investing.com Canada
Rapport Therapeutics stock holds Buy at TD Cowen on China deal - Investing.com Canada
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China - Bitget
Rapport Therapeutics and Tenacia Biotechnology Announce - GlobeNewswire
How Rapport Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - Naître et grandir
Published on: 2026-03-07 16:24:29 - baoquankhu1.vn
Is Rapport Therapeutics Inc. stock oversold or undervalued2025 Technical Overview & Weekly High Conviction Trade Ideas - Naître et grandir
Rapport Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Risks Report: Is Rapport Therapeutics Inc a stock for growth or value investorsWeekly Trend Recap & Expert Approved Trade Ideas - baoquankhu1.vn
TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday - MarketBeat
RAPP Should I Buy - Intellectia AI
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
RAPP PE Ratio & Valuation, Is RAPP Overvalued - Intellectia AI
Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling a 73.63% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Buyout Rumor: What is the cash position of Rapport Therapeutics Inc2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Highs Report: What hedge funds are buying Rapport Therapeutics IncGap Down & Consistent Return Investment Signals - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):